Hemogenyx Pharmaceuticals PLC Directorate Change & Appointment (2678G)
November 05 2018 - 2:00AM
UK Regulatory
TIDMHEMO
RNS Number : 2678G
Hemogenyx Pharmaceuticals PLC
05 November 2018
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Directorate Change and Appointment of Financial Controller and
Company Secretary
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments designed to transform
bone marrow transplantation for the treatment of blood diseases,
announces that Andrew Wright has been appointed as Financial
Controller & Company Secretary, a non-Board position, and that
Lawrence Pemble, Chief Operating Officer, will step down from the
Board, both with immediate effect.
Andrew began his career in audit at PricewaterhouseCoopers and
has an MBA in Finance and Strategy from the UCLA Anderson School of
Management in Los Angeles, USA. He serves as Director of Corporate
Development and Technology for Thomas Murray, a post-trade capital
markets data and advisory firm. Andrew is also an Executive
Director of Trayned Insight Ltd, a data science company serving the
healthcare and pharmaceutical industries.
Dr. Vladislav Sandler, CEO of Hemogenyx, commented:
"I am delighted to welcome Andrew to the team and look forward
to his support as we continue to advance the development of our
novel therapeutic products for patients with blood and severe
autoimmune diseases. I would also like to extend my thanks to
Lawrence for his contribution to the Board and we wish him well in
his next ventures."
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer Via Walbrook PR
& Co-Founder
Sir Marc Feldmann, Executive Chairman
Northland Capital Partners Limited Tel: +44 (0)20 3861 6625
Matthew Johnson, Vadim Alexandre, Dugald J
Carlean
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
Walbrook PR (UK Media & Investor Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Relations)
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned US operating
subsidiary, Hemogenyx LLC, located in Brooklyn, New York at its
state-of-the-art research facility ("Hemogenyx").
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
used only as a last resort and its use is restricted. Hemogenyx's
technology has the potential to enable many more patients suffering
from devastating blood diseases, such as leukemia and lymphoma, as
well as severe autoimmune diseases, such as multiple sclerosis,
aplastic anemia and systemic lupus erythematosus (Lupus), to
benefit from bone marrow transplantation.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFKQDQABDDNDK
(END) Dow Jones Newswires
November 05, 2018 02:00 ET (07:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024